Practical benefit of [ 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease

European Journal of Nuclear Medicine

Volumn 24, Issue 1, 1997, Pages 68-71

  Booij, J ^a,d   Tissingh, G ^b   Winogrodzka, A ^b   Boer, G J ^c   Stoof, J C ^b   Wolters, E C ^b   Van Royen, E A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cocaine analogues; Dopamine transporter imaging; Parkinson's disease; Single photon emission tomography

Indexed keywords

COCAINE DERIVATIVE; DOPAMINE TRANSPORTER; IODINE 123; N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)TROPANE; POTASSIUM IODIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; COCAINE; DIAGNOSTIC AGENT; DOPAMINE; DOPAMINE RECEPTOR; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOACTIVE IODINE; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PARKINSON DISEASE; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; CASE CONTROL STUDY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; SCINTISCANNING;

BRAIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RECEPTORS, DOPAMINE; TROPANES;

EID: 0030614355     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01728311     Document Type: Article

References (11)

1. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm /Gen Sect/ 1993; 94: 137-146.
2. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
3. 123I]β-CIT binding with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 1995; 22: 985-991.
4. 123I]β-CIT in vivo binding to dopamine transporters in healthy subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
5. 123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons. Nucl Med Biol 1995; 22: 211-219.
6. Neumeyer JL, Wang S, Guo Y, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 1558-1561.
7. 11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolic studies, and positron emission tomography examinations. Nucl Med Biol 1995; 22: 905-913.
8. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996; 37: 1129-1133.
9. Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethocy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22: 356-360.
10. 123I]FP-CIT SPECT reveals marked decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; in press.
11. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.